Abstracts Archive - Page 2378 of 2425 - ACR Meeting Abstracts

Abstract Number: 665 • 2012 ACR/ARHP Annual Meeting
Cytokines and Their Relation to Autoantibodies Before Disease Onset in Systemic Lupus Erythematosus
Catharina Eriksson¹ and Solbritt Rantapää Dahlqvist², ¹Department of Clinical Immunology/clinical microbiology, Umeå, Sweden, ²Department of Public Health and Clinical Medicine/Rheumatology, Umeå University Hospital, Umeå, Sweden
Background/Purpose: Cytokines and autoantibodies are involved in the pathogenesis of systemic lupus erythematosus (SLE). The presence of autoantibodies preceding disease onset by years has been…
Abstract Number: 666 • 2012 ACR/ARHP Annual Meeting
Leukadherin 1, a CR3 Mimetic, Negatively Regulates Toll Like Receptor (TLR) Dependent Inflammatory Responses via Degradation of an Adaptor Protein
Kristen Lee¹, Joanne H. Reed², Vineet Gupta³, Tejaskumar Patel², Jill P. Buyon⁴ and Robert M. Clancy², ¹Rheumatology, NYU Langone Medical Center, New York, NY, ²Medicine, New York University School of Medicine, New York, NY, ³Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miami, FL 33136, U.S.A., Miami, FL, ⁴Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Systemic Lupus Erythematosus is characterized by continuous and cyclic stimulation of the innate immune system by endogenous nucleic acids. Immune complexes of Ro60, ssRNA…
Abstract Number: 667 • 2012 ACR/ARHP Annual Meeting
Interferon-Alpha Impairs the Survival and Function of Circulating Angiogenic Cells in Vitro: A Model of Failed Endothelial Repair in SLE
John A. Reynolds¹, David W. Ray², Terence O'Neill³, M. Yvonne Alexander⁴ and Ian N. Bruce⁵, ¹Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, United Kingdom, Manchester, United Kingdom, ²Institute of Human Development, Institute of Human Development, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁴Healthcare Science Research Institute, Faculty of Science and Engineering, Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, ⁵Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Patients with Systemic Lupus Erythematosus have an increased risk of cardiovascular disease (CVD). No specific targeted therapies for CVD in lupus exist and there…
Abstract Number: 668 • 2012 ACR/ARHP Annual Meeting
Markers of Nitric Oxide and Hydroxyl Radical Formation Are Increased in Proliferative Lupus Nephritis and May Emanate From Increased Nitric Oxide Synthase and NADPH Oxidase Production and Reduced Endothelial Nitric Oxide Synthase-Derived NO Scavenging
Jim Oates¹, Ahmad Mashmoushi¹, Thomas Fleury¹, Ann Hofbauer¹ and Gary S. Gilkeson², ¹Medicine, Medical University of South Carolina, Charleston, SC, ²Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: The role of redox regulation of cell function in the different International Society of Nephrology/Renal Pathology Society (ISN/RPS) classes of lupus nephritis (LN) is…
Abstract Number: 669 • 2012 ACR/ARHP Annual Meeting
Serum Anti N-Methyl-D-Aspartate Receptor Subunit 1 Antibodies Are Elevated in SLE
Ogawa Eisuke, Nagai Tatsuo, Arinuma Yoshiyuki and Hirohata Shunsei, Rheumatology and infectious diseases, Kitasato University School of Medicine, Kanagawa, Japan
Background/Purpose: Previous studies have demonstrated that the presence of autoantibodies against N-methyl-D-aspartate (NMDA) receptor subunit 2 (NR2) is closely associated with brain damages leading to…
Abstract Number: 670 • 2012 ACR/ARHP Annual Meeting
Prolidase Deficiency Induces Antibodies to Sm, Ro60 and Double Stranded DNA
Biji T. Kurien¹, Anil D'souza², Skyler P. Dillon¹, Benjamin F. Bruner³, Timothy Gross⁴, Judith A. James⁵, Ira N. Targoff⁶, Jacen S. Maier-Moore⁷, Isaac T.W. Harley⁸, Heng Wang⁹ and Robert H. Scofield⁷, ¹Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ²Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Harding University, Searcy, AR, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Arthritis and Immunology, Oklahoma Medical Research Foun, Oklahoma City, OK, ⁷Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ⁸Cincinnati Children's Hospital Research Foundation, Cincinnati, OH, ⁹Das Deutsch Center Clinic for Special Needs Children, Middlefield, OH
Background/Purpose: Prolidase is a ubiquitous enzyme found in the cytoplasm. The enzyme specifically cleaves dipeptides containing C-terminal proline or hydroxyproline, in one of the last…
Abstract Number: 631 • 2012 ACR/ARHP Annual Meeting
Peripheral Neuropathy Due to Systemic Lupus Erythematosus (SLE) Itself: Incidence, Disease Risk Factors and Outcome
Simone Fargetti¹, Samuel K. Shinjo², Sandra G. Pasoto¹, Ana L. Calich¹, Eloisa Bonfa³ and Eduardo F. Borba¹, ¹Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ³Rheumatology Division, University of São Paulo, Sao Paulo, Brazil
Background/Purpose: Peripheral neuropathy (PN) solely attributable to SLE itself is difficult to define since most of these patients are exposed to several other conditions that…
Abstract Number: 632 • 2012 ACR/ARHP Annual Meeting
The Effects of Co-Existing Proliferative Histopathology On Membranous Lupus Nephritis
Jennifer L. Graybill¹, Catarina Vila-Inda¹, Chaim Putterman² and Irene Blanco¹, ¹Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Lupus nephritis (LN) affects up to 60% of SLE patients and is worse in minority communities. Traditionally membranous LN confers a better prognosis than…
Abstract Number: 633 • 2012 ACR/ARHP Annual Meeting
Missed Work Days in Systemic Lupus Erythematosus
Jie Xu¹, Hong Fang² and Michelle Petri², ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Indirect costs are part of the medical and financial burden of SLE. These costs are easy to undervalue because a significant portion of this…
Abstract Number: 634 • 2012 ACR/ARHP Annual Meeting
Adherence to Adult Treatment Panel III Guidelines for Systemic Lupus Patients
Matthew Basiaga and Lisabeth Scalzi, Rheumatology, Penn State Univ/ Hershey, Hershey, PA
Background/Purpose: The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) has provided education and guidance for decades on the management of hypercholesterolemia.…
Abstract Number: 635 • 2012 ACR/ARHP Annual Meeting
Elevated Transglutaminase Levels On Microparticles From Systemic Lupus Erythematosus Patients
Leslie Harris¹, Ratnesh Chopra¹, Ann K. Rosenthal² and Mary E. Cronin³, ¹Division of Rheumatology/Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, ²Div of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ³Rheumatology, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Systemic Lupus Erythematosus ( SLE) is characterized by the formation of autoantibodies, and over-exuberant antigen presentation may account for some of this pathology .…
Abstract Number: 636 • 2012 ACR/ARHP Annual Meeting
Retrospective Study of Allogenic Mesenchymal Stem Cells Transplantation in Active and Refractory Lupus Nephritis for Induction Therapy
Lingyun Sun, Dandan Wang, Xia Li and Huayong Zhang, Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Allogenic mesenchymal stem cells (MSCs) transplantation demonstrated significant clinical efficacy on various autoimmune diseases. Here we retrospectively analyzed the role of allogenic MSCs transplantation…
Abstract Number: 637 • 2012 ACR/ARHP Annual Meeting
Anti-Mullerian Hormone and Ovarian Reserve in Systemic Lupus Erythematosus
Chi Chiu Mok¹, Pak To Chan² and Chi Hung To², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Medicine, Hong Kong, Hong Kong
Background/Purpose: To study the level of anti-mullerian hormone (AMH) and its relationship with age and previous cyclophosphamide (CYC) exposure in patients with systemic lupus erythematosus…
Abstract Number: 638 • 2012 ACR/ARHP Annual Meeting
The Progression of Brain MRI Biomarker of Cognitive Impairment (White Matter Hyperintensity) in Systemic Lupus: A Clinical and Imaging Longitudinal Study
Jamal Mikdashi¹ and Umran Ashruf², ¹Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD, ²Radiology and Diagnostic Imaging, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: SLE patients are at high risk for accumulation of white matter hyperintensity (WMH) on brain MRI which has been correlated with cognitive impairment. Our…
Abstract Number: 639 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Epratuzumab in an Open-Label Extension Study (SL0006)
K. Hobbs¹, D.J. Wallace², V. Strand³, K. Kalunian⁴, B. Kilgallen⁵, S. Bongardt⁶, W.A. Wegener⁷ and D.M. Goldenberg⁷, ¹Denver Arthritis Clinic, Denver, CO, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³Biopharmaceutical Consultant, Portola Valley, CA, ⁴Center for Innovative Therapy, UCSD School of Medicine, La Jolla, CA, ⁵UCB Pharma, Smyrna, GA, ⁶UCB Pharma, Brussels, Belgium, ⁷Immunomedics Inc, Morris Plains, NJ
Background/Purpose: Epratuzumab, a monoclonal antibody targeting CD22, is in development for the treatment of systemic lupus erythematosus (SLE). Two randomized, double-blind trials (ALLEVIATE 1 and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].